SMITH & NEPHEW (SUZHOU) LIMITED
6 recall(s) on record — most severe on record: Class II.
Activity by year
- Recalls (6)
Devices registered here (1)
- Elastomer, Silicone, For Scar ManagementProduct code MDA (opens in a new tab) · Class I · General, Plastic Surgery · 21 CFR 878.4025
Recalls & enforcement
- Class IIOngoing2016-11-11Lack of 510k clearance for design modification.
- Class IIOngoing2016-07-21Sterility seal integrity failures on the Renasys Sterile Transparent Film
- Class IITerminated2014-08-13Modification were made to the RENASYS EZ NPWT Systems without a 510(k) or PreMarket Approval notification.
- Class IITerminated2014-07-18RENASYS EZ Canisters exhibiting visible evidence of deformation of the inlet port on the canister lid.
- Class IITerminated2014-01-09Reports of wound fluid and /or blood that were not evacuated from beneath the wound dressing and the pump blockage alarm did not activate has been associated with inadequate Soft Port sealing at the wound site or improper positioning of the Soft Port orifice over the wound contac…
- Class IITerminated2013-11-14Modification of the bacterial overflow guard (filter) and related changes to product labeling.
Related
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)
Cite this record
RegWarden. “SMITH & NEPHEW (SUZHOU) LIMITED (FEI 3007841320) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3007841320-smith-nephew-suzhou-limited/
Alerts for SMITH & NEPHEW (SUZHOU) LIMITED
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.